Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer.

White RR, Xie HB, Gottfried MR, Czito BG, Hurwitz HI, Morse MA, Blobe GC, Paulson EK, Baillie J, Branch MS, Jowell PS, Clary BM, Pappas TN, Tyler DS.

Ann Surg Oncol. 2005 Mar;12(3):214-21.

PMID:
15827813
2.

The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.

Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F.

J Gastrointest Surg. 2009 Jul;13(7):1337-44. doi: 10.1007/s11605-009-0919-2.

PMID:
19418101
3.

Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas.

White RR, Hurwitz HI, Morse MA, Lee C, Anscher MS, Paulson EK, Gottfried MR, Baillie J, Branch MS, Jowell PS, McGrath KM, Clary BM, Pappas TN, Tyler DS.

Ann Surg Oncol. 2001 Dec;8(10):758-65.

PMID:
11776488
4.

Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.

Barbour AP, Jones M, Gonen M, Gotley DC, Thomas J, Thomson DB, Burmeister B, Smithers BM.

Ann Surg Oncol. 2008 Oct;15(10):2894-902. doi: 10.1245/s10434-008-0084-y.

PMID:
18663531
5.

Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators.

Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD.

J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79.

PMID:
11307091
6.

Postoperative chemoradiotherapy of pancreatic cancer: what is the appropriate target volume of radiation therapy?

Kim K, Kim S, Chie EK, Kim SW, Bang YJ, Ha SW.

Tumori. 2005 Nov-Dec;91(6):493-7.

PMID:
16457148
7.

American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.

Rizk NP, Venkatraman E, Bains MS, Park B, Flores R, Tang L, Ilson DH, Minsky BD, Rusch VW; American Joint Committee on Cancer..

J Clin Oncol. 2007 Feb 10;25(5):507-12.

PMID:
17290058
8.

Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium.

Miller RC, Iott MJ, Corsini MM.

Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):364-8. doi: 10.1016/j.ijrobp.2008.11.069. Review.

PMID:
19735864
9.

Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma.

Brown KM, Siripurapu V, Davidson M, Cohen SJ, Konski A, Watson JC, Li T, Ciocca V, Cooper H, Hoffman JP.

Am J Surg. 2008 Mar;195(3):318-21. doi: 10.1016/j.amjsurg.2007.12.017.

PMID:
18308038
10.

Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.

Le Scodan R, Mornex F, Partensky C, Mercier C, Valette PJ, Ychou M, Roy P, Scoazec JY.

Am J Clin Oncol. 2008 Dec;31(6):545-52. doi: 10.1097/COC.0b013e318172d5c5.

PMID:
19060585
11.

Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas.

Langer R, Ott K, Feith M, Lordick F, Siewert JR, Becker K.

Mod Pathol. 2009 Dec;22(12):1555-63. doi: 10.1038/modpathol.2009.123.

12.

The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma.

Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Rice DC, Vaporciyan AA, Walsh GL, Roth JA, Wu TT, Swisher SG.

Cancer. 2006 Sep 1;107(5):967-74.

13.

Evaluation of preoperative therapy for pancreatic cancer using a prognostic nomogram.

White RR, Kattan MW, Haney JC, Clary BM, Pappas TN, Tyler DS, Brennan MF.

Ann Surg Oncol. 2006 Nov;13(11):1485-92.

PMID:
17013688
14.

REG I expression predicts long-term survival among locally advanced thoracic squamous cell esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy.

Motoyama S, Sugiyama T, Ueno Y, Okamoto H, Takasawa S, Nanjo H, Watanabe H, Maruyama K, Okuyama M, Ogawa J.

Ann Surg Oncol. 2006 Dec;13(12):1724-31.

PMID:
17009160
15.

Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers.

Lim SB, Choi HS, Jeong SY, Kim DY, Jung KH, Hong YS, Chang HJ, Park JG.

Ann Surg. 2008 Aug;248(2):243-51. doi: 10.1097/SLA.0b013e31817fc2a0.

PMID:
18650634
16.

Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.

Chao YK, Chan SC, Liu YH, Chen HW, Wan YL, Chang HK, Fan KH, Liu HP.

Ann Surg. 2009 Mar;249(3):392-6. doi: 10.1097/SLA.0b013e3181949e9f.

PMID:
19247024
17.

Nodal microinvolvement in patients with carcinoma of the papilla of vater receiving no adjuvant chemotherapy.

Bogoevski D, Chayeb H, Cataldegirmen G, Schurr PG, Kaifi JT, Mann O, Yekebas EF, Izbicki JR.

J Gastrointest Surg. 2008 Nov;12(11):1830-7; discussion 1837-8. doi: 10.1007/s11605-008-0683-8.

PMID:
18791769
18.

Is duodenal invasion a relevant prognosticator in patients undergoing adjuvant chemoradiotherapy for distal common bile duct cancer?

Kim K, Chie EK, Jang JY, Kim SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW.

Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1186-90. doi: 10.1016/j.ijrobp.2009.06.033.

PMID:
19962835
19.

[Histologic response after neoadjuvant therapy in rectal adenocarcinoma: own experience and review of the literature].

Mátrai Z, Lövey J, Hitre E, Orosz Z, Gödény M, Péley G, Sulyok Z, Rényi Vámos F, Farkas E, Köves I.

Orv Hetil. 2006 Oct 22;147(42):2011-20. Review. Hungarian.

PMID:
17165600
20.

Supplemental Content

Support Center